Cytokinetics

Highly Engaged Employees

Cytokinetics is a clinical-stage biopharmaceutical company established in 1998, specializing in the discovery, development, and commercialization of muscle activators and inhibitors. The firm focuses on addressing debilitating diseases where muscle performance is compromised, leveraging deep scientific expertise in muscle biology. Headquartered in South San Francisco, California, the company operates across three locations, maintaining a robust pipeline of novel small-molecule drug candidates designed to improve patient outcomes in areas of significant unmet medical need.

The organization maintains a workforce of 500-1,000 employees, including over 100 scientists and extensive operations teams dedicated to clinical research and development. Meet Cytokinetics's team to understand the leadership and technical expertise driving their biopharmaceutical innovation. The company’s operational footprint supports its mission to deliver first-in-class therapies, utilizing advanced biotechnology platforms to target specific muscle proteins like troponin. Their commitment to scientific rigor is reflected in their ongoing clinical trials and strategic focus on specialty medicine.

Cytokinetics, traded on the NASDAQ under the ticker CYTK, reported annual revenue of $67.7M. As a publicly traded entity, the company continues to navigate the competitive landscape of the healthcare sector, facing competition from firms like Amicus Therapeutics and Ultragenyx. Explore financial highlights to review detailed metrics regarding their funding history, including significant capital raises from institutional investors like Royalty Pharma and Goldman Sachs. The company remains a key player in the biopharmaceutical industry, consistently advancing its therapeutic candidates through rigorous clinical evaluation and commercialization strategies.